Related Experiment Videos

Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response

Dan Turner1, David Mack, Neal Leleiko

  • 1Shaare Zedek Medical Center, Jerusalem, Israel.

Gastroenterology
|March 3, 2010
PubMed

Insights

The Pediatric UC Activity Index (PUCAI) effectively identifies children with severe ulcerative colitis (UC) who may not respond to intravenous corticosteroids. Early PUCAI scores predict the need for salvage therapy, including infliximab, which shows promise in steroid-refractory cases.

Area of Science:

  • Pediatric Gastroenterology
  • Inflammatory Bowel Disease Research
  • Clinical Trial Analysis

Background:

  • Severe ulcerative colitis (UC) in children presents significant management challenges.
  • Identifying non-responders to initial intravenous corticosteroid therapy is crucial for timely intervention.

Purpose of the Study:

  • To assess outcomes in children with severe UC treated with intravenous corticosteroids.
  • To identify predictors of nonresponse to corticosteroids and evaluate salvage therapies.

Main Methods:

  • A prospective study enrolled 128 children with severe UC across 10 pediatric centers.
  • Clinical data, laboratory values, and the Pediatric UC Activity Index (PUCAI) were collected.
  • Patients were followed for 1 year postdischarge to assess outcomes.

Main Results:

  • 29% of children failed intravenous corticosteroids, with 89% receiving infliximab as salvage therapy.
  • The PUCAI, particularly on days 3 and 5, strongly predicted corticosteroid response and need for salvage therapy.
  • Infliximab treatment led to response in 25 of 33 children; cumulative colectomy rates were 9% at discharge and 19% at 1 year.

Conclusions:

  • The PUCAI is a valuable tool for identifying pediatric UC patients requiring salvage therapy within days of initiating corticosteroids.
  • Infliximab demonstrates efficacy as a salvage therapy for steroid-refractory pediatric UC.
  • Early PUCAI scores predict long-term response and outcomes in severe pediatric UC.
Abstract

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...